PRQR: ProQR Therapeutics N.V. Net earnings per share for the last 12 months
Innovative RNA editing methods and patent protection shield ProQR Therapeutics N.V. (PRQR) from price wars. Analyzing the rolling net income per share metric on GURU.Markets, we see that the indicator value reaches -0.46. ProQR Therapeutics N.V. (PRQR) focuses on correcting mutations for orphan centers, establishing scientific alliances with global industry leaders to combat rare pathologies.
%20Earnings%20per%20share%20for%20the%20last%20four%20quarters&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_PRQR_-_ProQR-Therapeutics-N.V._-_Earnings-per-share-for-the-last-four-quarters "ProQR Therapeutics N.V. - PRQR Net earnings per share (EPS TTM) (period 07/04/2022 - 11/14/2026) | 👁️GURU.Markets👁️")
Analytical breakdowns for ProQR Therapeutics NV (PRQR)
- share price and expert price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- business debt structure and liquidity details:
Debt to Equity ProQR Therapeutics N.V.|PRQR - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital ProQR Therapeutics N.V.|PRQR - Company Aggregate Debts|Debt to Book Capitalization Ratio ProQR|PRQR - Long-Term Liabilities|Company Short-Term Debts ProQR Therapeutics N.V.|Quick Liquidity Indicator proqr.com
- net income and valuation multiples indicators:
PRQR - Net Profit|Future Profit ProQR Therapeutics N.V.|PRQR - Market Price to Net Income Ratio|Forward P/E Multiple ProQR|PRQR - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple PRQR|PRQR - Operating profit before deduction of amortization|Earnings per share for the last twelve months ProQR Therapeutics N.V.|PRQR - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months proqr.com|PRQR - Earnings per share increase in current year|Net earnings per share growth forecast for next year ProQR Therapeutics N.V.
- issuer revenue and sales details:
Analysis of all company metrics:PRQR - ProQR Therapeutics
Net income per share over 12 months measures the final profitability of the business by distributing total income among all security holders to assess the real impact of operating expenses. Given the expenditures of ProQR Therapeutics N.V. (PRQR) to retain Axiomer platform experts and its partnership with Eli Lilly, the current trailing twelve-month net income per share reflects capital management efficiency and the resilience of fundamental value.
Key competitors
TEM: Net earnings per share for the last 12 months|QGEN (Qiagen Group) - Earnings per share for the last 12 months|Ionis (IONS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Repligen Inc. (RGEN)|RNA (Avidity Biosciences) - Net earnings per share (EPS TTM)|CRSP (CRISPR Therapeutics AG) - Earnings per share for the last four quarters|Earnings per share for the last twelve months GeneDx (WGS)|RARE - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) BEAM (Beam Therapeutics Inc)|Earnings per share for the trailing year SRPT|twistbioscience.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year TXG (10x Genomics, Inc.)|NTLA: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months STOK (Stoke Therapeutics, Inc.)|Net earnings per share for the last 12 months BLFS|Net earnings per one share for the last twelve months Wave Pharma WVE|Net earnings per share for the last 12 months MAZE (Maze Tx)|SION - Net earnings per one share for the last twelve months|Prime Medicine - Net earnings per share for the last 12 months|Taysha Gene Therapies Inc (TSHA) - Net earnings per one share for the last twelve months|uniqure.com - Net earnings per share (EPS TTM)|Net earnings per share for the trailing year MeiraGTx Corp (MGTX)|REGENXBIO (RGNX) - Earnings per share for the last twelve months|SLDB - Net earnings per share for the last four quarters|OCGN (ocugen.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Pacific Biosciences of California, Inc. PACB|Net earnings per share (EPS TTM) BNTC|Net earnings per share for the last four quarters Design Pharma|Net earnings per share (EPS TTM) RCKT (Rocket Corp)|FDMT - Net earnings per share for the last 12 months|Lexeo - Net earnings per share (EPS TTM)|KRRO - Net earnings per share (EPS TTM)|EDIT: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months SLN|CDXS (Codexis Inc) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months sangamo.com (SGMO)|Net earnings per share (EPS TTM) NAUT|Net earnings per share (EPS TTM) Metagenomi (MGX)|Earnings per share for the last twelve months Precision BioSciences DTIL|Net earnings per share (EPS TTM) Generation Bio Corp GBIO|Boundless Bio, Inc. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Exicure Inc.|Imunon, Inc. (IMNN) - Earnings per share for the last twelve months|RXi Pharmaceuticals (PHIO) - Net earnings per share (EPS TTM)|MBIO (Mustang Bio Corp) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months RNAZ (TransCode Therapeutics)|Net earnings per share (EPS TTM) BNGO|APDN: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) BLUE (bluebird bio Inc.)|Net earnings per share for the last four quarters ImmunoPrecise Antibodies (IPA)|OMGA: Net earnings per share for the last 12 months|OMIC (Singular Genomics Systems Inc) - Earnings per share for the last 12 months|Regulus Therapeutics (RGLS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months syros.com (SYRS)|TBIO (Telesis Bio Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months TRACON Pharmaceuticals Inc. (TCON)|Net earnings per share for the last 12 months UBX (Unity Biotechnology, Inc.)
